Related Experiment Video
Updated: Jul 4, 2026
10:26
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 11, 2014
Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma
A Kathrine Lie1, Gunnar Kristensen
1Department of Pathology, The Norwegian Radium Hospital, Rikshospitalet, N-0310 Oslo, Norway. akl@radiumhospitalet.no
Expert Review of Molecular Diagnostics
|July 5, 2008
Summary
Human papillomavirus (HPV) E6/E7 mRNA testing shows promise for identifying women at risk of cervical cancer. This RNA-based diagnostic may improve upon HPV DNA testing for screening and patient management.
Area of Science:
- Oncology
- Virology
- Molecular Diagnostics
Background:
- Human papillomavirus (HPV) is essential for cervical carcinoma development.
- HPV DNA testing is recommended for specific clinical scenarios but not primary screening due to limitations.
- Accurate, reproducible, and clinically useful HPV diagnostics are needed for cervical cancer screening programs.
Purpose of the Study:
- To provide an overview of RNA-based HPV diagnostics.
- To explore the role of E6/E7 mRNA detection as a predictive marker for cervical carcinoma.
- To evaluate the potential of HPV E6/E7 mRNA testing in cervical cancer screening and management.
Main Methods:
- Review of RNA-based HPV diagnostic methods.
- Analysis of E6/E7 mRNA detection as a biomarker.
- Discussion of commercial assays for high-risk HPV types.
Main Results:
- HPV E6/E7 mRNA testing correlates better with lesion severity than HPV DNA testing.
- E6/E7 mRNA detection is a potential marker for identifying women at risk of cervical cancer.
- Commercial assays for simultaneous genotyping and E6/E7 mRNA detection are available.
Conclusions:
- HPV E6/E7 mRNA testing offers a promising approach for cervical cancer risk assessment.
- This RNA-based method may enhance the accuracy of HPV diagnostics.
- Further evaluation of commercial E6/E7 mRNA assays is required for primary screening, triage, and follow-up.
